Takeda and its oncology-focused subsidiary Millennium have published positive new clinical trial data for the multiple myeloma treatment Velcade.
Final five-year follow-up data from the phase III Vista trial has shown that Velcade, in combination with melphalan and prednisone (MP), can offer clinical benefits among previously untreated multiple myeloma patients compared to MP alone.
The Velcade-based therapy was demonstrated to offer a 13.3-month increase in median overall survival rates over the course of the study in comparison to MP, a recognised standard of care.
Professor Jesus San Miguel of the Hospital Clinico Universitario de Salamanca said: "This data confirms that starting previously untreated multiple myeloma patients with the Velcade-based combination provided a significant survival advantage over MP."
Velcade is approved in more than 90 countries worldwide and is marketed in Europe by Janssen-Cilag, with Millennium handling US sales operations.
It was one of a number of oncology therapies discussed by Millennium at the American Society of Hematology annual meeting, with early-stage compounds such as MLN8237 and MLN9708 also receiving coverage.See all the latest jobs in Pharmaceutical